Dose Individualization of Pemetrexed - IMPROVE-II
Launched by RADBOUD UNIVERSITY MEDICAL CENTER · Aug 30, 2018
Trial Information
Current as of May 17, 2025
Terminated
Keywords
ClinConnect Summary
No description provided
Gender
ALL
Eligibility criteria
- Inclusion Criteria:
- • 1. ≥18 years old
- • 2. Eligible for treatment with pemetrexed-based chemotherapy
- • 3. Creatinine clearance \>45ml/min
- • 4. Eastern Cooperative Oncology Group (ECOG) performance score of 0-2
- • 5. Subject is able and willing to sign the Informed Consent Form
- Exclusion Criteria:
- • 1. Conditions that affect haemostasis in a way that blood drawing is complicated (to be assessed by physician)
- • 2. Contraindications for treatment with pemetrexed in line with the summary of product characteristics (SmPC) (except for creatinine clearance \<45 ml/min in IMPROVE-I)
- • 1. Hypersensitivity to the active substance or to any of the excipients
- • 2. Pregnancy or lactation
- • 3. Concomitant yellow fever vaccine
- • 3. The presence of clinically relevant pharmacokinetic interactions, according to the current SmPC
About Radboud University Medical Center
Radboud University Medical Center is a leading academic medical institution located in Nijmegen, the Netherlands, dedicated to advancing healthcare through innovative research and education. As a prominent sponsor of clinical trials, Radboud UMC leverages its multidisciplinary expertise to conduct high-quality research that aims to improve patient outcomes and enhance medical knowledge. The center is committed to ethical standards and regulatory compliance, fostering collaboration among researchers, healthcare professionals, and patients to translate scientific discoveries into effective clinical applications. With a focus on personalized medicine and cutting-edge technologies, Radboud University Medical Center plays a pivotal role in shaping the future of healthcare through its rigorous clinical trial initiatives.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Nijmegen, , Netherlands
'S Hertogenbosch, , Netherlands
Maastricht, , Netherlands
Amsterdam, , Netherlands
Rotterdam, , Netherlands
Patients applied
Trial Officials
Rob ter Heine, PhD
Principal Investigator
Radboud University Medical Center
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials